Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 446

1.

Predicting Dangerous Rides in CAR T Cells: Bridging the Gap between Mice and Humans.

Ruella M, June CH.

Mol Ther. 2018 May 18. pii: S1525-0016(18)30208-9. doi: 10.1016/j.ymthe.2018.05.005. [Epub ahead of print] No abstract available.

PMID:
29784587
2.

Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia.

Fraietta JA, Lacey SF, Orlando EJ, Pruteanu-Malinici I, Gohil M, Lundh S, Boesteanu AC, Wang Y, O'Connor RS, Hwang WT, Pequignot E, Ambrose DE, Zhang C, Wilcox N, Bedoya F, Dorfmeier C, Chen F, Tian L, Parakandi H, Gupta M, Young RM, Johnson FB, Kulikovskaya I, Liu L, Xu J, Kassim SH, Davis MM, Levine BL, Frey NV, Siegel DL, Huang AC, Wherry EJ, Bitter H, Brogdon JL, Porter DL, June CH, Melenhorst JJ.

Nat Med. 2018 May;24(5):563-571. doi: 10.1038/s41591-018-0010-1. Epub 2018 Apr 30.

PMID:
29713085
3.

The CPT1a inhibitor, etomoxir induces severe oxidative stress at commonly used concentrations.

O'Connor RS, Guo L, Ghassemi S, Snyder NW, Worth AJ, Weng L, Kam Y, Philipson B, Trefely S, Nunez-Cruz S, Blair IA, June CH, Milone MC.

Sci Rep. 2018 Apr 19;8(1):6289. doi: 10.1038/s41598-018-24676-6.

4.

Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma.

Garfall AL, Stadtmauer EA, Hwang WT, Lacey SF, Melenhorst JJ, Krevvata M, Carroll MP, Matsui WH, Wang Q, Dhodapkar MV, Dhodapkar K, Das R, Vogl DT, Weiss BM, Cohen AD, Mangan PA, Ayers EC, Nunez-Cruz S, Kulikovskaya I, Davis MM, Lamontagne A, Dengel K, Kerr ND, Young RM, Siegel DL, Levine BL, Milone MC, Maus MV, June CH.

JCI Insight. 2018 Apr 19;3(8). pii: 120505. doi: 10.1172/jci.insight.120505. [Epub ahead of print]

5.

Immunotherapy for Breast Cancer: Current and Future Strategies.

Williams AD, Payne KK, Posey AD Jr., Hill C, Conejo-Garcia J, June CH, Tchou J.

Curr Surg Rep. 2017 Dec;5. pii: 31. Epub 2017 Oct 10.

6.

Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer.

Tanyi JL, Bobisse S, Ophir E, Tuyaerts S, Roberti A, Genolet R, Baumgartner P, Stevenson BJ, Iseli C, Dangaj D, Czerniecki B, Semilietof A, Racle J, Michel A, Xenarios I, Chiang C, Monos DS, Torigian DA, Nisenbaum HL, Michielin O, June CH, Levine BL, Powell DJ Jr., Gfeller D, Mick R, Dafni U, Zoete V, Harari A, Coukos G, Kandalaft LE.

Sci Transl Med. 2018 Apr 11;10(436). pii: eaao5931. doi: 10.1126/scitranslmed.aao5931.

PMID:
29643231
7.

Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses.

Watanabe K, Luo Y, Da T, Guedan S, Ruella M, Scholler J, Keith B, Young RM, Engels B, Sorsa S, Siurala M, Havunen R, Tähtinen S, Hemminki A, June CH.

JCI Insight. 2018 Apr 5;3(7). pii: 99573. doi: 10.1172/jci.insight.99573. [Epub ahead of print]

8.

Improving CART-Cell Therapy of Solid Tumors with Oncolytic Virus-Driven Production of a Bispecific T-cell Engager.

Wing A, Fajardo CA, Posey AD Jr, Shaw C, Da T, Young RM, Alemany R, June CH, Guedan S.

Cancer Immunol Res. 2018 May;6(5):605-616. doi: 10.1158/2326-6066.CIR-17-0314. Epub 2018 Mar 27.

PMID:
29588319
9.

CAR T cell immunotherapy for human cancer.

June CH, O'Connor RS, Kawalekar OU, Ghassemi S, Milone MC.

Science. 2018 Mar 23;359(6382):1361-1365. doi: 10.1126/science.aar6711. Review.

PMID:
29567707
10.

Activity of Mesothelin-specific Chimeric Antigen Receptor T cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial.

Beatty GL, O'Hara MH, Lacey SF, Torigian DA, Nazimuddin F, Chen F, Kulikovskaya IM, Soulen MC, McGarvey M, Nelson AM, Gladney WL, Levine BL, Melenhorst JJ, Plesa G, June CH.

Gastroenterology. 2018 Mar 19. pii: S0016-5085(18)30323-8. doi: 10.1053/j.gastro.2018.03.029. [Epub ahead of print]

PMID:
29567081
11.

CAR T Cell Therapy for Glioblastoma: Recent Clinical Advances and Future Challenges.

Bagley SJ, Desai AS, Linette GP, June CH, O'Rourke DM.

Neuro Oncol. 2018 Mar 2. doi: 10.1093/neuonc/noy032. [Epub ahead of print]

PMID:
29509936
12.

Gut microbiota modulates adoptive cell therapy via CD8α dendritic cells and IL-12.

Uribe-Herranz M, Bittinger K, Rafail S, Guedan S, Pierini S, Tanes C, Ganetsky A, Morgan MA, Gill S, Tanyi JL, Bushman FD, June CH, Facciabene A.

JCI Insight. 2018 Feb 22;3(4). pii: 94952. doi: 10.1172/jci.insight.94952. [Epub ahead of print]

13.

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.

Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, Bader P, Verneris MR, Stefanski HE, Myers GD, Qayed M, De Moerloose B, Hiramatsu H, Schlis K, Davis KL, Martin PL, Nemecek ER, Yanik GA, Peters C, Baruchel A, Boissel N, Mechinaud F, Balduzzi A, Krueger J, June CH, Levine BL, Wood P, Taran T, Leung M, Mueller KT, Zhang Y, Sen K, Lebwohl D, Pulsipher MA, Grupp SA.

N Engl J Med. 2018 Feb 1;378(5):439-448. doi: 10.1056/NEJMoa1709866.

PMID:
29385370
14.

GLYCAN-DIRECTED CAR-T CELLS.

Steentoft C, Migliorini D, King TR, Mandel U, June CH, Posey AD Jr..

Glycobiology. 2018 Jan 23. doi: 10.1093/glycob/cwy008. [Epub ahead of print]

PMID:
29370379
15.

Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation.

Guedan S, Posey AD Jr., Shaw C, Wing A, Da T, Patel PR, McGettigan SE, Casado-Medrano V, Kawalekar OU, Uribe-Herranz M, Song D, Melenhorst JJ, Lacey SF, Scholler J, Keith B, Young RM, June CH.

JCI Insight. 2018 Jan 11;3(1). pii: 96976. doi: 10.1172/jci.insight.96976. [Epub ahead of print]

16.

Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas.

Schuster SJ, Svoboda J, Chong EA, Nasta SD, Mato AR, Anak Ö, Brogdon JL, Pruteanu-Malinici I, Bhoj V, Landsburg D, Wasik M, Levine BL, Lacey SF, Melenhorst JJ, Porter DL, June CH.

N Engl J Med. 2017 Dec 28;377(26):2545-2554. doi: 10.1056/NEJMoa1708566. Epub 2017 Dec 10.

PMID:
29226764
17.

Human CD26high T cells elicit tumor immunity against multiple malignancies via enhanced migration and persistence.

Bailey SR, Nelson MH, Majchrzak K, Bowers JS, Wyatt MM, Smith AS, Neal LR, Shirai K, Carpenito C, June CH, Zilliox MJ, Paulos CM.

Nat Commun. 2017 Dec 6;8(1):1961. doi: 10.1038/s41467-017-01867-9.

18.

Retroviral and Lentiviral Safety Analysis of Gene-Modified T Cell Products and Infused HIV and Oncology Patients.

Marcucci KT, Jadlowsky JK, Hwang WT, Suhoski-Davis M, Gonzalez VE, Kulikovskaya I, Gupta M, Lacey SF, Plesa G, Chew A, Melenhorst JJ, Levine BL, June CH.

Mol Ther. 2018 Jan 3;26(1):269-279. doi: 10.1016/j.ymthe.2017.10.012. Epub 2017 Oct 20.

PMID:
29203150
19.

CAR T-Cell Therapies in Glioblastoma: A First Look.

Migliorini D, Dietrich PY, Stupp R, Linette GP, Posey AD Jr, June CH.

Clin Cancer Res. 2018 Feb 1;24(3):535-540. doi: 10.1158/1078-0432.CCR-17-2871. Epub 2017 Nov 20.

PMID:
29158268
20.

Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer.

Tchou J, Zhao Y, Levine BL, Zhang PJ, Davis MM, Melenhorst JJ, Kulikovskaya I, Brennan AL, Liu X, Lacey SF, Posey AD Jr, Williams AD, So A, Conejo-Garcia JR, Plesa G, Young RM, McGettigan S, Campbell J, Pierce RH, Matro JM, DeMichele AM, Clark AS, Cooper LJ, Schuchter LM, Vonderheide RH, June CH.

Cancer Immunol Res. 2017 Dec;5(12):1152-1161. doi: 10.1158/2326-6066.CIR-17-0189. Epub 2017 Nov 6.

PMID:
29109077
21.

Cytokine release syndrome associated with chimeric-antigen receptor T-cell therapy: clinicopathological insights.

Obstfeld AE, Frey NV, Mansfield K, Lacey SF, June CH, Porter DL, Melenhorst JJ, Wasik MA.

Blood. 2017 Dec 7;130(23):2569-2572. doi: 10.1182/blood-2017-08-802413. Epub 2017 Oct 26. No abstract available.

PMID:
29074500
22.

Genome-Editing Technologies in Adoptive T Cell Immunotherapy for Cancer.

Singh N, Shi J, June CH, Ruella M.

Curr Hematol Malig Rep. 2017 Dec;12(6):522-529. doi: 10.1007/s11899-017-0417-7. Review.

PMID:
29039115
23.

Human Genome Editing in the Clinic: New Challenges in Regulatory Benefit-Risk Assessment.

Abou-El-Enein M, Cathomen T, Ivics Z, June CH, Renner M, Schneider CK, Bauer G.

Cell Stem Cell. 2017 Oct 5;21(4):427-430. doi: 10.1016/j.stem.2017.09.007.

PMID:
28985524
24.

Absence of Replication-Competent Lentivirus in the Clinic: Analysis of Infused T Cell Products.

Cornetta K, Duffy L, Turtle CJ, Jensen M, Forman S, Binder-Scholl G, Fry T, Chew A, Maloney DG, June CH.

Mol Ther. 2018 Jan 3;26(1):280-288. doi: 10.1016/j.ymthe.2017.09.008. Epub 2017 Sep 12.

PMID:
28970045
25.

Augmentation of Antitumor Immunity by Human and Mouse CAR T Cells Secreting IL-18.

Hu B, Ren J, Luo Y, Keith B, Young RM, Scholler J, Zhao Y, June CH.

Cell Rep. 2017 Sep 26;20(13):3025-3033. doi: 10.1016/j.celrep.2017.09.002.

26.

Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia.

Mueller KT, Maude SL, Porter DL, Frey N, Wood P, Han X, Waldron E, Chakraborty A, Awasthi R, Levine BL, Melenhorst JJ, Grupp SA, June CH, Lacey SF.

Blood. 2017 Nov 23;130(21):2317-2325. doi: 10.1182/blood-2017-06-786129. Epub 2017 Sep 21.

27.

Corrigendum: Is autoimmunity the Achilles' heel of cancer immunotherapy?

June CH, Warshauer JT, Bluestone JA.

Nat Med. 2017 Aug 4;23(8):1004. doi: 10.1038/nm0817-1004b. No abstract available.

PMID:
28777789
28.

Generating and Expanding Autologous Chimeric Antigen Receptor T Cells from Patients with Acute Myeloid Leukemia.

Kenderian SS, June CH, Gill S.

Methods Mol Biol. 2017;1633:267-276. doi: 10.1007/978-1-4939-7142-8_17.

PMID:
28735493
29.

A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma.

O'Rourke DM, Nasrallah MP, Desai A, Melenhorst JJ, Mansfield K, Morrissette JJD, Martinez-Lage M, Brem S, Maloney E, Shen A, Isaacs R, Mohan S, Plesa G, Lacey SF, Navenot JM, Zheng Z, Levine BL, Okada H, June CH, Brogdon JL, Maus MV.

Sci Transl Med. 2017 Jul 19;9(399). pii: eaaa0984. doi: 10.1126/scitranslmed.aaa0984.

30.

Ibrutinib treatment improves T cell number and function in CLL patients.

Long M, Beckwith K, Do P, Mundy BL, Gordon A, Lehman AM, Maddocks KJ, Cheney C, Jones JA, Flynn JM, Andritsos LA, Awan F, Fraietta JA, June CH, Maus MV, Woyach JA, Caligiuri MA, Johnson AJ, Muthusamy N, Byrd JC.

J Clin Invest. 2017 Aug 1;127(8):3052-3064. doi: 10.1172/JCI89756. Epub 2017 Jul 17.

31.

Immunotherapy for Brain Tumors.

Sampson JH, Maus MV, June CH.

J Clin Oncol. 2017 Jul 20;35(21):2450-2456. doi: 10.1200/JCO.2017.72.8089. Epub 2017 Jun 22. Review.

PMID:
28640704
32.

Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells.

Ruella M, Klichinsky M, Kenderian SS, Shestova O, Ziober A, Kraft DO, Feldman M, Wasik MA, June CH, Gill S.

Cancer Discov. 2017 Oct;7(10):1154-1167. doi: 10.1158/2159-8290.CD-16-0850. Epub 2017 Jun 2.

PMID:
28576927
33.

Novel T cells with improved in vivo anti-tumor activity generated by RNA electroporation.

Liu X, Jiang S, Fang C, Li H, Zhang X, Zhang F, June CH, Zhao Y.

Protein Cell. 2017 Jul;8(7):514-526. doi: 10.1007/s13238-017-0422-6. Epub 2017 May 18.

34.

Is autoimmunity the Achilles' heel of cancer immunotherapy?

June CH, Warshauer JT, Bluestone JA.

Nat Med. 2017 May 5;23(5):540-547. doi: 10.1038/nm.4321. Erratum in: Nat Med. 2017 Aug 4;23 (8):1004.

35.

In Vitro Induction of Human Regulatory T Cells Using Conditions of Low Tryptophan Plus Kynurenines.

Hippen KL, O'Connor RS, Lemire AM, Saha A, Hanse EA, Tennis NC, Merkel SC, Kelekar A, Riley JL, Levine BL, June CH, Turka LA, Kean LS, MacMillan ML, Miller JS, Wagner JE, Munn DH, Blazar BR.

Am J Transplant. 2017 Dec;17(12):3098-3113. doi: 10.1111/ajt.14338. Epub 2017 Jun 14.

PMID:
28470889
36.

Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer.

Hege KM, Bergsland EK, Fisher GA, Nemunaitis JJ, Warren RS, McArthur JG, Lin AA, Schlom J, June CH, Sherwin SA.

J Immunother Cancer. 2017 Mar 21;5:22. doi: 10.1186/s40425-017-0222-9. eCollection 2017.

37.

Studying Immunoreceptor Signaling in Human T Cells Using Electroporation of In Vitro Transcribed mRNA.

Kawalekar O, June CH, Milone MC.

Methods Mol Biol. 2017;1584:443-450. doi: 10.1007/978-1-4939-6881-7_27.

PMID:
28255718
38.

Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia.

Tasian SK, Kenderian SS, Shen F, Ruella M, Shestova O, Kozlowski M, Li Y, Schrank-Hacker A, Morrissette JJD, Carroll M, June CH, Grupp SA, Gill S.

Blood. 2017 Apr 27;129(17):2395-2407. doi: 10.1182/blood-2016-08-736041. Epub 2017 Feb 28.

39.

Possible Compartmental Cytokine Release Syndrome in a Patient With Recurrent Ovarian Cancer After Treatment With Mesothelin-targeted CAR-T Cells.

Tanyi JL, Stashwick C, Plesa G, Morgan MA, Porter D, Maus MV, June CH.

J Immunother. 2017 Apr;40(3):104-107. doi: 10.1097/CJI.0000000000000160.

PMID:
28234665
40.

Cancer Killers.

Posey AD Jr, June CH, Levine BL.

Sci Am. 2017 Feb 14;316(3):38-43. doi: 10.1038/scientificamerican0317-38. No abstract available.

PMID:
28207696
41.

A versatile system for rapid multiplex genome-edited CAR T cell generation.

Ren J, Zhang X, Liu X, Fang C, Jiang S, June CH, Zhao Y.

Oncotarget. 2017 Mar 7;8(10):17002-17011. doi: 10.18632/oncotarget.15218.

42.

The Principles of Engineering Immune Cells to Treat Cancer.

Lim WA, June CH.

Cell. 2017 Feb 9;168(4):724-740. doi: 10.1016/j.cell.2017.01.016. Review.

43.

Oncolytic Adenoviral Delivery of an EGFR-Targeting T-cell Engager Improves Antitumor Efficacy.

Fajardo CA, Guedan S, Rojas LA, Moreno R, Arias-Badia M, de Sostoa J, June CH, Alemany R.

Cancer Res. 2017 Apr 15;77(8):2052-2063. doi: 10.1158/0008-5472.CAN-16-1708. Epub 2017 Jan 31.

44.

PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR.

Chong EA, Melenhorst JJ, Lacey SF, Ambrose DE, Gonzalez V, Levine BL, June CH, Schuster SJ.

Blood. 2017 Feb 23;129(8):1039-1041. doi: 10.1182/blood-2016-09-738245. Epub 2016 Dec 28. No abstract available.

45.

Driving gene-engineered T cell immunotherapy of cancer.

Johnson LA, June CH.

Cell Res. 2017 Jan;27(1):38-58. doi: 10.1038/cr.2016.154. Epub 2016 Dec 27. Review.

46.

Drugging the Undruggable Ras - Immunotherapy to the Rescue?

June CH.

N Engl J Med. 2016 Dec 8;375(23):2286-2289. No abstract available.

PMID:
27959676
47.

Optimization of cGMP purification and expansion of umbilical cord blood-derived T-regulatory cells in support of first-in-human clinical trials.

McKenna DH Jr, Sumstad D, Kadidlo DM, Batdorf B, Lord CJ, Merkel SC, Koellner CM, Curtsinger JM, June CH, Riley JL, Levine BL, Miller JS, Brunstein CG, Wagner JE, Blazar BR, Hippen KL.

Cytotherapy. 2017 Feb;19(2):250-262. doi: 10.1016/j.jcyt.2016.10.011. Epub 2016 Nov 22.

48.

Potent and Broad Inhibition of HIV-1 by a Peptide from the gp41 Heptad Repeat-2 Domain Conjugated to the CXCR4 Amino Terminus.

Leslie GJ, Wang J, Richardson MW, Haggarty BS, Hua KL, Duong J, Secreto AJ, Jordon AP, Romano J, Kumar KE, DeClercq JJ, Gregory PD, June CH, Root MJ, Riley JL, Holmes MC, Hoxie JA.

PLoS Pathog. 2016 Nov 17;12(11):e1005983. doi: 10.1371/journal.ppat.1005983. eCollection 2016 Nov.

49.

Distinguishing Truncated and Normal MUC1 Glycoform Targeting from Tn-MUC1-Specific CAR T Cells: Specificity Is the Key to Safety.

Posey AD Jr, Clausen H, June CH.

Immunity. 2016 Nov 15;45(5):947-948. doi: 10.1016/j.immuni.2016.10.015.

50.

Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition.

Ren J, Liu X, Fang C, Jiang S, June CH, Zhao Y.

Clin Cancer Res. 2017 May 1;23(9):2255-2266. doi: 10.1158/1078-0432.CCR-16-1300. Epub 2016 Nov 4.

Supplemental Content

Support Center